← boardnext 2028-11
BDTX
Black Diamond Therapeutics, Inc.distress 5/10 · elevated risk$1.81-1%today-63% from 52w high
Oncology 1
Lead: NSCLC · target EGFR
Revenue
pre-revenue
Liquidity
$30M
Runway
0.9 yrs
Shares 1y
+1%
Price & events
-31.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
+0.3%
1W
+12.7%
1M
-41.5%
3M
-30.5%
6M
-43.1%
1Y
-70.8%
2Y
-80.6%
5Y
-94.4%
All
Overview
- Market Cap
- $104.00M
- Volume
- 27.87K
- 52 Week Range
- $1.61 – $4.87
- Total Shares
- 57.30M
- Float Shares
- 52.45M
- Short %
- 11.30%
- % Held by Insiders
- 0.65%
- % Held by Institutions
- 67.24%
- RVOL
- 0.02x
- Beta
- 3.25
Pipeline stages · 2 programs
silevertinib in combination with temozolomide, temozolomide (TMZ)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
silevertinib (BDTX-1535) monotherapyEGFR
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-11 Estimated 50% readout ~2028-12-16 | Phase 2 | silevertinib in combination with temozolomide, temozolomide (TMZ) | Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer | — | recruiting |
| 2025-11-03 | Phase 1/2 | silevertinib (BDTX-1535) monotherapy | Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation | 200 | active not recruiting |
Catalyst news & presentations · 6
- 2028Guided 40%readoutPhase 2Silevertinib · Preliminary data expected from GBM Phase 2 trial.SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026conferencedata presentationsecondaryPhase 2Silevertinib · Present updated DOR and PFS results at a medical meeting.SEC 8-K
- first half of 2026trial initiationsecondaryPhase 2Silevertinib · Initiate randomized Phase 2 trial in newly diagnosed GBM.SEC 8-K
- Q1 2025readoutPhase 2BDTX-1535 · Initial Phase 2 data in frontline settingSEC 8-K
- 2025-03-18partnershipBDTX-4933 · Global licensing agreement with Servier for BDTX-4933 in solid tumors, including NSCLC, with $70M upfront and up to $710M in milestones.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-29BTIGBuy
- 2026-03-17WedbushOutperform
- 2026-01-16Piper SandlerOverweight
- 2025-12-04GuggenheimBuy → Neutral
- 2025-10-01Freedom BrokerBuy
- 2025-09-04GuggenheimBuy
Competitors — EGFR
Recent news
- 2026-07-15BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview - ChartMill
- 2026-07-13Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary - Quartr
- 2026-07-11Black Diamond Therapeutics (BDTX) Edges Higher Amid Key Support Test - Seasonality Effect - dars.gov.et
- 2026-07-08T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment - Stock Titan
- 2026-07-06Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
- 2026-07-04BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
- 2026-07-01Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth - simplywall.st
- 2026-07-01Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth - Sahm
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.